Generic Reyvow Availability
Last updated on Apr 10, 2025.
Reyvow is a brand name of lasmiditan, approved by the FDA in the following formulation(s):
REYVOW (lasmiditan succinate - tablet;oral)
-
Manufacturer: ELI LILLY AND CO
Approval date: January 31, 2020
Strength(s): EQ 50MG BASE [RLD], EQ 100MG BASE [RLD] -
Manufacturer: ELI LILLY AND CO
Approval date: December 18, 2020
Strength(s): EQ 200MG BASE (discontinued) [RLD]
Is there a generic version of Reyvow available?
No. There is currently no therapeutically equivalent version of Reyvow available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reyvow. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods related to pyridinoylpiperidine 5-HTagonists
Patent 11,053,214
Issued: July 6, 2021
Inventor(s): Allieri Brigida & Fagan Paul & Sharp Emma & Skwierczynski Raymond D.
Assignee(s): CoLucid Pharmaceuticals, Inc.The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.
Patent expiration dates:
- December 5, 2037✓✓✓
- December 5, 2037
-
Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide ace
Patent 12,071,423
Issued: August 27, 2024
Inventor(s): Aburub; Aktham et al.
Assignee(s): Eli Lilly and Company (Indianapolis, IN)The embodiments of present invention provide processes for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
Patent expiration dates:
- July 6, 2040✓
- July 6, 2040
-
Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent 7,423,050
Issued: September 9, 2008
Inventor(s): Cohen; Michael Philip et al.
Assignee(s): Eli Lilly and Company (Indianapolis, IN)The present invention relates to compounds of formula I: ##STR00001## or pharmaceutically acceptable acid addition salts thereof, where; R.sup.1 is C.sub.1-C.sub.6 alkyl, substituted C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, substituted C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, substituted C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R.sup.2 is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.6 cycloalkyl-C.sub.1-C.sub.3 alkyl, or a group of formula II ##STR00002## R.sup.3 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.4 is hydrogen, halo, or C.sub.1-C.sub.3 alkyl; R.sup.5 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.6 is hydrogen or C.sub.1-C.sub.6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT.sub.1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
Patent expiration dates:
- February 17, 2028✓✓✓
- February 17, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- January 31, 2025 - NEW CHEMICAL ENTITY
More about Reyvow (lasmiditan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (23)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
